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Objective The phenotype of the antioxidant and pro-angiogenic
protein haptoglobin (Hp) predicts cardiovascular disease risk and
treatment response to antioxidant vitamins in individuals with
diabetes. Our objective was to determine whether Hp phenotype
influences pre-eclampsia risk, or the efficacy of vitamins C and E
in preventing pre-eclampsia, in women with type-1 diabetes.
Design This is a secondary analysis of a randomised controlled
trial in which women with diabetes received daily vitamins C and
E, or placebo, from 8 to 22 weeks of gestation until delivery.
Setting Twenty-five antenatal metabolic clinics across the UK (in
north-west England, Scotland, and Northern Ireland).
Population Pregnant women with type-1 diabetes.
Methods Hp phenotype was determined in white women who
completed the study and had plasma samples available (n = 685).
Main outcome measure Pre-eclampsia.
Results Compared with Hp 2-1, Hp 1-1 (OR 0.59, 95% CI 0.30–
1.16) and Hp 2-2 (OR 0.93, 95% CI 0.60–1.45) were not
associated with significantly decreased pre-eclampsia risk after
adjusting for treatment group and HbA1c at randomisation. Our
study was not powered to detect an interaction between Hp
phenotype and treatment response; however, our preliminary
analysis suggests that vitamins C and E did not prevent pre-
eclampsia in women of any Hp phenotype (Hp 1-1, OR 0.77, 95%
CI 0.22–2.71; Hp 2-1, OR 0.81, 95% CI 0.46–1.43; Hp 2-2, 0.67,
95% CI 0.34–1.33), after adjusting for HbA1c at randomisation.
Conclusions The Hp phenotype did not significantly affect pre-
eclampsia risk in women with type-1 diabetes.
Keywords Haptoglobin phenotype, pre-eclampsia, pregnancy,
type-1 diabetes, vitamin C, vitamin E.
Please cite this paper as: Weissgerber T, Gandley R, Roberts J, Patterson C, Holmes V, Young I, McCance D. Haptoglobin phenotype, pre-eclampsia, and
response to supplementation with vitamins C and E in pregnant women with type-1 diabetes. BJOG 2013;120:1192–1199.
Introduction
Pre-eclampsia affects 15–18% of women with type-1 diabe-
tes,1,2 leading to increased maternal and fetal morbidity
and mortality.3,4 Oxidative stress is associated with pre-
eclampsia,5,6 and the antioxidant vitamins C and E lowered
pre-eclampsia incidence by 60% among high-risk women
in a small randomised controlled trial (RCT).7 Unfortu-
nately, subsequent RCTs in high- and low-risk women,8–13
and in women with type-1 diabetes,14 were negative.
Although these divergent results are likely to reflect low
power in the small trial, differences could also be explained
by the greater diversity of patients in multicentre trials
masking a subset of responsive women.
Haptoglobin (Hp) is an antioxidant and pro-angiogenic
protein,15,16 with three generically determined phenotypes
(1-1, 2-1, and 2-2).17 Hp 1-1 is the strongest antioxidant.15
Hp 2-2 is the most angiogenic.16 Little is known about the
function of Hp 2-1, which is structurally distinct from Hp
1-1 and Hp 2-2.17 The Hp phenotype predicts cardiovascu-
lar risk,18,19 and responsiveness to vitamin E,20–22 or to
vitamins C and E,23 in individuals with diabetes.
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Basic science
We examined whether the Hp phenotype might affect
pre-eclampsia risk, or identify women with type-1 diabetes
who would respond to vitamin supplementation, for three
reasons. First, angiogenic imbalance and oxidative stress
contribute to pre-eclampsia,5,6 and the pro-angiogenic and
antioxidant properties of Hp are phenotype-dependant.16,17
In our recent study, Hp 2-1 was associated with a two-fold
greater pre-eclampsia risk among white women without
diabetes.24 Second, all three phenotypes are common in
white women (17–48%); therefore, any effect would affect
a large proportion of women.25 Third, Hp phenotype influ-
ences cardiovascular risk, and responsiveness to vitamin
E,20–22 or to vitamins C and E,23 in individuals with diabe-
tes. The cardiovascular event risk is doubled in Hp 2-2
individuals with diabetes, compared with Hp 1-1 and Hp
2-1 individuals with diabetes,20,23,26 and vitamin E elimi-
nates this increased risk.20,21,27 In contrast, vitamin C com-
bined with vitamin E is either beneficial or harmful,
depending on the Hp phenotype.23 In postmenopausal
women with coronary artery disease, vitamins C and E
decreased coronary artery diameter in Hp 2-2 women with
diabetes, but benefited Hp 1-1 women by increasing coro-
nary artery diameter.23
We performed a secondary analysis of an RCT of antiox-
idants to prevent pre-eclampsia in women with type-1 dia-
betes to determine whether Hp phenotype is associated
with pre-eclampsia risk, or antioxidant response, in these
women.14 We hypothesized that Hp 2-1 would be associ-
ated with an increased pre-eclampsia risk, in accordance
with our previous data from women without diabetes. We
also posited that the phenotype would affect treatment
response, although the nature of the effect was difficult to
predict using data from non-pregnant individuals.
Methods
Study population
This was a secondary analysis of a multicentre RCT (IS-
RCTN 27214045) in which 762 women with type-1 diabe-
tes received 1000 mg of vitamin C and 400 iu of vitamin
E, or placebo, daily from 8 to 22 weeks of gestation until
delivery. The trial was conducted from 2003 to 2008 in 25
antenatal metabolic clinics across the UK (in north-west
England, Scotland, and Northern Ireland). Full details have
been reported previously.14 The West Midlands multicentre
research ethics committee approved the study (MREC 02/
7/016). All subjects provided written, informed consent
prior to participating. Hp phenotypes were determined at
the University of Pittsburgh (Institutional Review Board
exempt approval PRO10090150; retrospective analysis of
samples already in existence).
The distribution of Hp phenotypes depends upon race.25
In the Diabetes and Pre-eclampsia Intervention Trial
(DAPIT), 96.5% of women were white (n = 735), 0.9%
were black (n = 7), 1.4% were Asian (n = 11), and 1.2%
were of other or unknown race (n = 9). The sample sizes
were too small to draw conclusions about women who
were not white; therefore, these women were excluded from
the analysis. Fifty white women were excluded because
plasma samples were not available. Hp phenotype was
determined in the remaining 685 white women. Ten
women who experienced fetal loss before 20 weeks of gesta-
tion were excluded from analyses examining the relation-
ship between Hp phenotype, pre-eclampsia risk, and
vitamin supplementation.
The primary outcome for the trial was pre-eclampsia,
defined as gestational hypertension and proteinuria accord-
ing to the International Society for the Study of Hyperten-
sion in Pregnancy guidelines at the time of the trial.28
Gestational hypertension was defined as two diastolic blood
pressure readings ≥90 mmHg, separated by at least 4 hours,
or a single diastolic blood pressure reading ≥110 mmHg,
between 20 weeks of gestation and 48 hours postpartum,
excluding labour. Proteinuria was defined as a dipstick
reading ≥1+ on at least two occasions, or a 24-hour urinary
protein ≥300 mg. Among women with pre-existing protein-
uria, pre-eclampsia was diagnosed if women had dipstick
readings of ≥ 2+, 24-hour urinary protein ≥600 mg, or one
or more other features of pre-eclampsia, such as those
defining the HELLP syndrome (haemolysis, elevated liver
enzymes, and low platelet count) or eclampsia. Secondary
outcomes for this analysis were severe pre-eclampsia and
early onset pre-eclampsia. Severe pre-eclampsia was defined
as pre-eclampsia accompanied by one or more of the fol-
lowing: diastolic blood pressure ≥110 mmHg, the highest
urine protein dipstick reading ≥3+, a urine output <500 ml
in 24 hour, grand mal seizures, blurred vision, headache,
pulmonary oedema, HELLP syndrome, or epigastric pain.
Data for early onset pre-eclampsia are presented as pre-
eclampsia with delivery before 34 or 37 weeks of gestation.
Haptoglobin phenotyping
Hp phenotype was determined as described previously.24
Native polyacrilamide gel electrophoresis (PAGE) was per-
formed on 5 ll of citrated plasma supplemented with 3 ll
of 25 lmol/l human haemoglobin (Sigma-Aldrich, St
Louis, MO, USA). Samples were run on 6% tris-glycine
gels (Invitrogen, Carlsbad, CA, USA) for 2 hours at 120 V,
then transferred to a polyvinylidene fluoride (PVDF) mem-
brane (Millipore, Billerica, MA, USA). The peroxidase
activity of the haemoglobin/Hp complex was used to visu-
alise the Hp phenotype.
Samples that were haemolysed or had low Hp concentra-
tions were phenotyped by SDS-PAGE.24 A 2-ll portion of
b-mercaptoethanol was added to 1–6 ll of serum. After
heating for 7 minutes at 82°C, samples were run on 15%
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tris-glycine gels at 120 V for 1.75 hours. Proteins were then
transferred to PVDF. Membranes were incubated with
blocking solution (tris-buffered saline containing 5%
non-fat milk, 0.1% Tween 20), primary antibody (1:5000,
polyclonal rabbit anti-human haptogloin; DakoCytomation,
Carpinteria, CA, USA) and secondary antibody (1:25 000,
goat anti-rabbit immunoglobulin G horseradish peroxidase;
Millipore) at room temperature for 1 hour each. Antibod-
ies were dissolved in blocking solution, and membranes
were washed in tris-buffered saline containing 0.1% Tween
20 between incubations.
Membranes from native and SDS-PAGE were stained for
peroxidase activity (SuperSignal West Pico Chemilumines-
cent Substrate; Fisher Scientific, Pittsburgh, PA, USA) and
imaged (FlouroChem Q System; Cell Biosciences, Santa
Clara, CA, USA). Hp phenotypes were identified by their
characteristic banding patterns (Figure 1).
Statistical analysis
Quantitative variables were summarized using means and
standard deviations unless distributions were heavily
skewed, in which case medians and interquartile ranges
were used. Comparisons of characteristics between Hp phe-
notype groups were performed using one-way analysis of
variance, Kruskal–Wallis analysis of variance of ranks, or
the chi-square test. Logistic regression analysis was used to
compare the risks of pre-eclampsia in the phenotype
groups. The 2-1 phenotype was selected as the reference
category, as this was the phenotype with the largest sample
size. Logistic regression was performed both before and
after adjustment for two potential confounding factors,
treatment group (vitamins or placebo) and HbA1c category
at randomisation (≤6.0, 6.0–6.9, 7.0–7.9, ≥8.0%, or
unknown). Logistic regression was also used to check if the
effect of vitamin supplementation on pre-eclampsia risk
differed between the three Hp phenotype groups by adding
the interaction between Hp phenotype and treatment group
to the model.
Results
Subject characteristics
The prevalence of the Hp 1-1 (14.7%), Hp 2-1 (48.7%),
and Hp 2-2 (36.6%) phenotypes were similar to previously
reported values for white men and women.25 Women with
the Hp 2-1 phenotype were randomised slightly earlier than
women with the Hp 1-1 or Hp 2-2 phenotypes, and this
small difference was the only statistically significant differ-
ence (P < 0.05) found in 19 comparisons (Table 1). Hp
phenotype groups did not differ with respect to maternal
demographic characteristics (age, parity, and education),
physical characteristics (body mass index, blood pressure,
and albumin-creatinine ratio at randomisation), health
behaviours (smoking, and consumption of multivitamins
or aspirin prior to randomisation), diabetes history (dura-
tion, HbA1c, and insulin dose at randomisation), or hyper-
tension (hypertension or antihypertensive treatment before
pregnancy, previous pre-eclampsia).
Hp phenotype and pre-eclampsia risk
There was no significant difference in the risk of pre-eclamp-
sia, severe pre-eclampsia, or early onset pre-eclampsia
between the three phenotype groups (Table 2). Compared
with Hp 2-1, Hp 1-1 and Hp 2-2 were not associated with a
significantly decreased risk of pre-eclampsia, severe pre-
eclampsia, or early onset pre-eclampsia (Table 3). Adjust-
ment for treatment group (vitamins C and E versus placebo)
and HbA1c category at randomisation had a minimal effect
on the odds ratios.
Hp phenotype and treatment response
There was no significant interaction between the effect of
Hp phenotype and the effect of vitamin supplementation
on pre-eclampsia risk (P = 0.87). Odds ratios for the devel-
opment of pre-eclampsia with vitamin supplementation
were 0.67 (95% CI 0.15–2.67) in Hp 1-1, 0.82 (95% CI
0.45–1.51) in Hp 2-1, and 0.66 (95% CI 0.32–1.36) in Hp
2-2 (Table 4). Supplementation with vitamins C and E did
not significantly reduce pre-eclampsia risk in white women
with type-1 diabetes of any Hp phenotype.
A B
Figure 1. Hp phenotypes by Native and SDS PAGE. (A) Hp
phenotyping of Hb-supplemented plasma by Native PAGE on a 6% gel
using Hb peroxidase detection. Hp 1-1 has a single fast-migrating band
(lane 2). Hp 2-2 has a series of slowly migrating bands (lane 6). Hp 2-1
(lanes 1 and 3–5) has one band between the Hb/Hp 1-1 and Hb/Hp 2-2
bands, and several slowly migrating bands in the same region as the
Hb/Hp 2-2 bands. (B) Hp phenotyping of plasma by SDS-PAGE on a
12% gel with western blotting. All phenotypes have the Hp b band.
The a1 band indicates that the Hp 1 allele is present. The a2 band
indicates that the Hp 2 allele is present. Hp 2-2 has a2 and b bands
(lane 1), Hp 2-1 has a1, a2 and b bands (lane 2), and Hp 1-1 has a1 and
b bands (lane 3).
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Discussion
This secondary analysis of an RCT of daily supplementa-
tion with vitamins C and E to prevent pre-eclampsia
reveals two important findings.14 First, Hp phenotype was
not associated with pre-eclampsia risk in white women
with type-1 diabetes. Second, although our study was not
powered to detect an interaction between Hp phenotype
and treatment, we found no evidence that vitamins C and
E significantly affect pre-eclampsia risk in women of any
Hp phenotype.
Hp phenotype and pre-eclampsia risk
When we began this investigation, two small, underpow-
ered case–control studies in women without diabetes had
reported that pre-eclampsia risk was either increased or did
not differ in Hp 1-1 women.29,30 Cohort studies, adequately
powered studies, and studies in women with diabetes were
needed. A subsequent Israeli study in women without dia-
betes reported a lower pre-eclampsia risk among Hp 1-1
women, compared with Hp 2-1 and Hp 2-2 women (5.8
versus 12.5%).31 Our larger case–control study indicated
that Hp 1-1 was protective in comparison with Hp 2-1,
but not with Hp 2-2, in white women without diabetes.24
Racial differences between populations may have contrib-
uted to these divergent results in women without diabetes;
however, the small sample sizes of early studies suggest that
spurious findings may also have been a factor.
Table 1. Maternal demographic characteristics
Variable Hp 1-1
(n = 99)
Hp 2-1
(n = 335)
Hp 2-2
(n = 251)
P
Age (years)* 29.7  5.7 29.6  5.5 29.8  5.6 0.96
Gestational age at randomisation (weeks)* 14.2  3.3 13.7  3.3 14.4  3.6 0.05
Body mass index at randomisation (kg/m2)* 28.0  5.2 27.8  5.5 27.1  4.2 0.15
Current smoker** 21 (21%) 75 (22%) 40 (16%) 0.14
Primiparous** 44 (44%) 170 (51%) 118 (47%) 0.46
12 years or fewer of full-time education** 36 (36%) 132 (39%) 96 (38%) 0.85
Taking multivitamin at randomisation** 12 (12%) 33 (10%) 26 (10%) 0.81
Taking aspirin at randomisation** 5 (5%) 23 (7%) 18 (7%) 0.77
Antihypertensive treatment before pregnancy** 7 (7%) 28 (8%) 24 (10%) 0.74
Hypertension before pregnancy** 18 (18%) 49 (15%) 37 (15%) 0.68
Blood pressure at entry (8–22 weeks; mmHg)
Systolic* 120.1  12.3 118.0  11.6 119.9  12.1 0.11
Diastolic* 76.1  8.8 74.1  8.1 75.1  9.0 0.09
Pre-eclampsia in previous pregnancy** 14 (14%) 40 (12%) 22 (9%) 0.28
Diabetes
Duration (years)* 14.6  7.9 14.1  8.0 15.1  8.5 0.38
HbA1c at randomisation* 7.3  1.1 7.2  1.0 7.1  0.9 0.47
Insulin at randomisation (units/day)*** 60 (43–74) 58 (42–74) 54 (44–68) 0.24
Renal status before index pregnancy***
Normal 87 (88%) 307 (92%) 230 (92%) 0.56
Microalbuminuria 7 (7%) 14 (4%) 11 (4%)
Macroalbuminuria 1 (1%) 3 (1%) 0 (0%)
Urinary protein >3 g/24 hours 0 (0%) 2 (1%) 2 (1%)
Not known 4 (4%) 9 (3%) 8 (3%)
Albumin:creatinine at randomisation (mg/mmol)*** 0.81 (0.46–1.98) 0.69 (0.36–1.47) 0.70 (0.41–1.53) 0.20
Values are means  SDs, median (interquartile range) or n (%).
*One-way ANOVA.
**Chi-square test.
***Kruskal–Wallis ANOVA of ranks.
Table 2. Pre-eclampsia incidence according to Hp phenotype
Outcome Hp 1-1
(n = 99)
Hp 2-1
(n = 329)
Hp 2-2
(n = 247)
P
Pre-eclampsia 12 (12.1%) 59 (17.9%) 42 (17.0%) 0.39
Severe pre-eclampsia 10 (10.1%) 53 (16.1%) 33 (13.4%) 0.29
Early onset pre-eclampsia
<34 weeks 2 (2.0%) 12 (3.6%) 6 (2.4%) 0.58
<37 weeks 10 (10.1%) 41 (12.5%) 24 (9.7%) 0.55
Values are n (%). Groups were compared using the chi-square test.
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The present study extends the existing literature to
include women with type-1 diabetes. This is particularly
important, as the impact of Hp phenotype on cardiovascu-
lar disease risk,18,19 and on responsiveness to antioxidant
vitamins,20–23 in non-pregnant populations is primarily
confined to individuals with diabetes. In the present study,
Hp phenotype was not associated with the risk of pre-
eclampsia, severe pre-eclampsia, or early onset pre-eclamp-
sia in white women with type-1 diabetes. Rates of pre-
eclampsia tended to be lower in Hp 1-1 women; however,
this effect was clearly not significant. Although the sample
size for this secondary analysis was limited by the low
number of participants in the RCT, the number of subjects
was sufficient to detect a 14% difference in pre-eclampsia
risk between Hp 1-1 and Hp 2-1 (12 versus 26%; 80%
power; a = 0.05). The study was not powered to detect
smaller differences. Despite this limitation, this is the only
study we are aware of that has examined women with
type-1 diabetes. The cohort design is also a significant
strength, as all studies in women without diabetes have
used a case–control design.
Hp phenotype and vitamins C and E
Emerging evidence suggests that there is a strong relation-
ship between pre-eclampsia and future cardiovascular dis-
ease. Pre-eclampsia and cardiovascular disease share many
risk factors (i.e. obesity, diabetes, being black, and hyperlip-
idaemia) and underlying pathophysiological processes
(endothelial dysfunction, angiogenic imbalance, inflamma-
tion, and oxidative stress).32,33 Pre-eclampsia is now recog-
nised as a risk factor for cardiovascular disease by the
American Heart Association.33 Hp phenotype affects both
cardiovascular disease risk and treatment response to anti-
oxidant vitamins in individuals with diabetes.20,21,23,26
Therefore, we examined the potential for Hp to modify the
efficacy of vitamins C and E in preventing pre-eclampsia in
women with type-1 diabetes.
Our study did not have sufficient power to detect an
interaction between Hp phenotype and treatment response;
however, our preliminary analysis provided no evidence
that supplementation with vitamins C and E prevented
pre-eclampsia among white women with type-1 diabetes of
any Hp phenotype. It is extremely unlikely that larger
Table 3. Odds ratios for pre-eclampsia
Outcome Phenotype n (% within group) OR (95% CI)* Adjusted OR (95% CI)*,**
Pre-eclampsia Controls
Pre-eclampsia 1-1 12 (10.6%) 87 (15.5%) 0.63 (0.32–1.23) 0.59 (0.30–1.16)
2-1 59 (52.2%) 270 (48.0%) 1 1
2-2 42 (37.2%) 205 (36.5%) 0.94 (0.61–1.45) 0.93 (0.60–1.45)
Severe pre-eclampsia 1-1 10 (10.4%) 87 (15.5%) 0.59 (0.29–1.20) 0.55 (0.27–1.13)
2-1 53 (55.2%) 270 (48.0%) 1 1
2-2 33 (34.4%) 205 (36.5%) 0.82 (0.51–1.31) 0.81 (0.50–1.31)
Early onset pre-eclampsia (<34 weeks) 1-1 2 (10.0%) 87 (15.5%) 0.52 (0.11–2.36) 0.47 (0.10–2.15)
2-1 12 (60.0%) 270 (48.0%) 1 1
2-2 6 (30.0%) 205 (36.5%) 0.66 (0.24–1.78) 0.68 (0.25–1.85)
Early onset pre-eclampsia (<37 weeks) 1-1 10 (13.3%) 87 (15.5%) 0.76 (0.36–1.57) 0.72 (0.35–1.51)
2-1 41 (54.7%) 270 (48.0%) 1 1
2-2 24 (32.0%) 205 (36.5%) 0.77 (0.45–1.32) 0.77 (0.45–1.32)
Statistical analysis was performed by logistic regression.
*Hp 2-1 was used as the reference group for all comparisons.
**Adjusted for treatment group and HbA1c at randomisation by category (≤6.0%, 6.0–6.9%, 7.0–7.9%, ≥8.0%, and unknown).
Table 4. Incidence of pre-eclampsia among women in the placebo and treatment groups
Phenotype Treatment Placebo OR (95% CI) P Adjusted OR (95% CI)* P
1-1 5/50 (10.0%) 7/49 (14.3%) 0.67 (0.20–2.26) 0.52 0.77 (0.22–2.71) 0.69
2-1 26/158 (16.5%) 33/171 (19.3%) 0.82 (0.47–1.45) 0.50 0.81 (0.46–1.43) 0.46
2-2 18/127 (14.2%) 24/120 (20.0%) 0.66 (0.34–1.29) 0.23 0.67 (0.34–1.33) 0.25
Statistical analysis was performed by logistic regression.
*Adjusted for HbA1c at randomisation by category (≤6.0%, 6.0–6.9%, 7.0–7.9%, ≥8.0%, and unknown).
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studies will ever be conducted. Several factors could con-
tribute to the difference between our study and previous
studies of cardiovascular disease risk in individuals with
diabetes.20,21,23,26 First, although pre-eclampsia and cardio-
vascular disease share many risk factors and pathophysio-
logical processes, there are important differences between
these two conditions. Pre-eclampsia is a pregnancy-specific
syndrome, in which one or more factors released by the
placenta are believed to contribute to maternal vascular
dysfunction.32 Factors that are only produced by the pla-
centa, or are released from the placenta in larger quantities
than from other tissues, are unlikely to play a major role in
cardiovascular disease.
Second, studies of cardiovascular disease suggest that
the effects of vitamin E alone differ from the effects of
combined vitamin C and E supplementation.20,21,27
Among postmenopausal women with coronary artery dis-
ease, vitamins C and E may be beneficial or harmful
depending on Hp phenotype.23 Supplementation increased
coronary artery diameter in Hp 1-1 women, and this ben-
eficial effect was stronger in Hp 1-1 women with diabe-
tes.23 In Hp 2-2 women with diabetes, however, the weak
antioxidant capacity of Hp 2-2 may have interacted with
the pro-oxidant effects of vitamin C to accelerate coro-
nary artery narrowing.23,24 Both type-1 diabetes and preg-
nancy increase oxidative stress,32,35 suggesting that a
similar mechanism could potentially be active in our
study population; however, we did not find evidence to
support this hypothesis.
Third, previous studies examining the interaction
between Hp phenotype and responsiveness to antioxidant
vitamins have focused on type-2 diabetes.21,26 Women in
the present study had type-1 diabetes. Hp 2-2 increases car-
diovascular disease risk in both type-1 and type-2 diabe-
tes.19,20 The purported mechanisms by which vitamin E
reduces risk (by modifying the adverse effects of glycosylat-
ed haemoglobin on high-density lipoprotein dysfunction34)
is likely to be similar in both conditions; however, the rela-
tionship between Hp phenotype, risk of cardiovascular dis-
ease and vitamin supplementation in type-1 diabetes has
not yet been investigated.
Conclusion
In contrast to the results of previous studies in women
without diabetes,24,31 Hp phenotype did not significantly
affect pre-eclampsia risk in white women with type-1
diabetes. Researchers have suggested that Hp phenotype
may identify a subgroup of women who would benefit
from antioxidant supplementation to prevent pre-eclamp-
sia.24,36 Although our study had limited power to detect
an interaction between Hp phenotype and treatment
response, our preliminary analysis did not suggest that
supplementation with vitamins C and E would modify
pre-eclampsia risk in women with type-1 diabetes of any
Hp phenotype. It remains possible that other types or
combinations of antioxidants may benefit women of spe-
cific Hp phenotypes; however, the absence of a relation-
ship between Hp phenotype and pre-eclampsia risk
makes this possibility unlikely.
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Weissgerber et al.
Commentary on ‘Haptoglobin phenotype, pre-eclampsia, and
response to supplementation with vitamins C and E in pregnant
women with type–1 diabetes’
Weissgerber and colleagues have reported a secondary biologic sample analysis from a large, multicentre clinical trial of
antioxidants for the prevention of pre-eclampsia in pregnant women with type–1 diabetes. Unfortunately, antioxidants
have now joined the list of failed pre-eclampsia prevention therapies, with numerous trials of high- and low-risk women
demonstrating no preventive benefit. That said, however, there still exists the possibility that antioxidants might prove
useful in appropriately identified subsets of the obstetric population. One such subset could be women with type–1 dia-
betes. Although almost all of the high- and low-risk antioxidant trials specifically excluded these women, the parent trial
from which these data and samples were derived (McCance DR et al. Lancet 2010;376:259–66) specifically studied anti-
oxidant pre-eclampsia prevention in pregnant type–1 diabetic women.
Haptoglobin (Hp) is an antioxidant protein that has two allelic forms and three genotypes. These three genotypes
have varying antioxidant potentials that, in non-pregnant diabetics, predict cardiovascular risk and antioxidant respon-
siveness. Unfortunately, the current study demonstrates that maternal Hp genotype does not identify any subsets of the
pregnant diabetic population that might benefit from antioxidant prophylaxis. The authors appropriately note that their
statistical power is limited, but also comment that larger antioxidant trials in pregnant diabetic populations are very
unlikely to be performed in the future.
In my opinion, this article has several important messages:
1. It is important to include diabetics in clinical trials. Although the proportion of pregnancies complicated by type–1
diabetes is well below 1%, these pregnancies consume disproportionate resources and represent substantial cost cen-
tres. We owe it not only to these women and their families, but to our respective health care systems, to specifically
include them in clinical trials in order to optimise their outcomes.
2. Genomic medicine is poised to make substantial inroads to obstetric practice. Essentially all of the ‘great obstetric syn-
dromes’ (certainly including pre-eclampsia) are final common pathways for many different etiologies, some of which
are recognized, and many of which are still unknown. As these pathophysiologic mechanisms are elucidated, persona-
lised preventions and treatments, like the hypothesis of this study, will rapidly proliferate. Likewise, over the next few
decades pharmacogenomics will surely improve therapeutic outcomes and reduce adverse drug reactions.
3. Clinical trial designers should always consider including in the consent process the possibility of biologic sample
banking (with the appropriate specification of uses) and of subsequent participant re-contact. This study was made
possible by the foresight of the investigators of the parent study, who provided the opportunity for the testing of mul-
tiple secondary hypotheses, many of which would not have been imaginable at the time the parent study was
designed. Access to these resources must also be as open as possible, consistent with viable scientific hypotheses.
The design of the parent study (focusing on diabetics), the accessibility of the data and biologic samples from the parent
study for viable secondary analyses, and the application of genomic testing to obstetric care all represent important clini-
cal research tenets that will contribute to improved outcomes and sustainable costs going forwards.&
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